NMS-293

N/A

Report date: 2026/04/30 20:00:20
NME

Base Information

Drug NameNMS-293
Drug Alias NameNMS-03305293NMS-P293NMS-293
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPoly (ADP-Ribose) polymerase inhibitors
TargetsPoly (ADP-Ribose) polymerase
Therapy Area/IndicationsSolid tumoursSmall Cell Lung CarcinomaOvarian Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBulgariaUnited StatesPuerto Rico +[8] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaDiscontinued
Originator CompaniesNerviano Medical Sciences Srl
China Registration ClassN/A

Develop Information

Active CompaniesNerviano Medical Sciences Srl
Inactive CompaniesMerck Healthcare Kgaa, Darmstadt, Germany, An Affiliate Of Merck Kgaa, Darmstadt, GermanyDmed Biopharmaceutical Co LtdNerPharMa SRL
Active IndicationsSmall Cell Lung CarcinomaOvarian NeoplasmsGlioblastoma +[4] 
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A